According to Gram Research analysis, cancer cells steal vitamin B2 from immune cells by using a different nutrient transporter, weakening the immune system’s ability to fight tumors. A 2026 study in Cell found that blocking cancer’s vitamin B2 transporter (SLC52A2) enhanced immune cell function and improved cancer immunotherapy effectiveness. Increasing vitamin B2 intake or engineering immune cells to grab more vitamin B2 could boost cancer treatment outcomes.
Scientists discovered that cancer cells compete with immune cells for vitamin B2, a nutrient that helps your body fight tumors. When cancer wins this competition, it weakens your immune system’s ability to attack the disease. Researchers found that giving more vitamin B2 or boosting immune cells’ ability to grab this nutrient could help cancer treatments work better. This discovery, published in Cell in 2026, opens new doors for improving immunotherapy, a type of cancer treatment that trains your body’s own cells to fight cancer.
Key Statistics
A 2026 study published in Cell found that tumors preferentially use the SLC52A2 transporter to scavenge vitamin B2, outcompeting T immune cells that rely on the SLC52A3 transporter for this critical nutrient.
Research shows that high levels of the SLC52A2 transporter in human tumors correlate with weak T cell function and poor patient survival outcomes, suggesting vitamin B2 competition is clinically significant in cancer.
In immunocompetent hosts, blocking tumor SLC52A2 enhanced T cell antitumor function without directly slowing intrinsic tumor growth, indicating that metabolic competition is a key mechanism of immune evasion.
Vitamin B2 supplementation or SLC52A3 overexpression augmented CAR-T cell antitumor efficacy in research models, suggesting practical approaches to improve advanced cancer immunotherapy.
The Quick Take
- What they studied: How cancer cells and immune cells compete for vitamin B2, and whether giving more vitamin B2 could help immune cells fight cancer better.
- Who participated: Researchers used laboratory models and immunocompetent hosts (animals with working immune systems) to study this competition. The study involved analyzing tumor samples and testing new approaches to boost immune cell function.
- Key finding: Cancer cells use a different vitamin B2 transporter (SLC52A2) than immune cells (SLC52A3) to steal this nutrient. When cancer cells were prevented from grabbing vitamin B2, immune cells became stronger and fought tumors more effectively without slowing tumor growth directly.
- What it means for you: This research suggests that vitamin B2 supplementation or enhanced immune cell engineering could improve cancer immunotherapy outcomes. However, this is early-stage research, and more human studies are needed before these approaches become standard treatment.
The Research Details
Researchers created a new platform called CareSLCs to identify how different cells transport nutrients. They discovered that vitamin B2 uptake is critical for T cells, a type of immune cell that fights cancer. The team studied what happens when T cells don’t get enough vitamin B2: their mitochondria (the cell’s power plants) stop working properly, iron builds up to toxic levels, and fats in the cell break down, ultimately killing the T cell through a process called ferroptosis.
The researchers then made a surprising discovery: cancer cells preferentially use a different vitamin B2 transporter (SLC52A2) than T cells use (SLC52A3). This means tumors have evolved a specialized way to steal vitamin B2 without directly competing with immune cells’ preferred uptake method. When scientists removed the SLC52A2 transporter from cancer cells in immunocompetent hosts, T cells became more powerful and fought tumors more effectively.
Finally, the team tested whether giving more vitamin B2 or engineering T cells to grab more vitamin B2 could improve CAR-T cell therapy, a cutting-edge cancer treatment. Both approaches worked, suggesting practical ways to boost this new immunotherapy strategy.
Understanding how cancer cells evade the immune system at the metabolic level is crucial for developing better cancer treatments. Most cancer research focuses on genetic mutations or surface proteins, but this study reveals that nutrient competition is a hidden mechanism of immune escape. By identifying the specific transporters involved, researchers can now design targeted interventions that don’t require changing cancer cells’ genetics.
This research was published in Cell, one of the world’s most prestigious scientific journals, indicating rigorous peer review. The study used multiple complementary approaches: the new CareSLCs platform for discovery, mechanistic studies to understand how vitamin B2 deficiency kills T cells, and functional validation in living organisms. The findings were tested in immunocompetent hosts, which better reflect real immune system function than isolated cell cultures. However, the abstract does not specify exact sample sizes for all experiments, and human clinical trials have not yet been conducted.
What the Results Show
The research established that vitamin B2 uptake through the SLC52A3 transporter is essential for T cell function. When T cells lack adequate vitamin B2, their mitochondria cannot generate enough energy, and they accumulate toxic iron and lipid damage, leading to ferroptosis (a type of cell death). This metabolic vulnerability represents a checkpoint where cancer can suppress immune function.
Cancer cells exploit this vulnerability by using the SLC52A2 transporter to preferentially scavenge vitamin B2 from the environment. This creates a metabolic competition where tumors outcompete T cells for this critical nutrient. Remarkably, removing SLC52A2 from cancer cells enhanced T cell function and improved antitumor immunity in living organisms, without directly slowing tumor growth through other mechanisms.
The clinical relevance became clear when researchers analyzed human tumor samples: high levels of SLC52A2 in tumors correlated with weak T cell function and worse patient survival outcomes. Conversely, people who consumed more dietary vitamin B2 had lower cancer risks, suggesting that adequate vitamin B2 intake may support immune surveillance.
When researchers either supplemented vitamin B2 or engineered T cells to overexpress SLC52A3, CAR-T cell therapy (an advanced immunotherapy) became significantly more effective at fighting cancer.
The study revealed the specific molecular chain of events triggered by vitamin B2 deficiency in T cells: impaired mitochondrial respiration leads to glutathione depletion (loss of a protective antioxidant), which allows iron to accumulate and lipids to break down. This cascade ultimately triggers ferroptosis. The research also showed that tumor SLC52A2 ablation enhanced T cell function specifically in immunocompetent hosts, suggesting that the immune system’s response is critical to the benefit.
Previous research recognized that tumors create metabolic stress for immune cells by competing for glucose and other nutrients. This study extends that understanding by identifying a specific nutrient (vitamin B2) and specific transporters (SLC52A2 vs. SLC52A3) that drive this competition. The discovery that cancer cells preferentially use a different transporter than immune cells is novel and suggests that tumors have evolved sophisticated strategies to avoid direct nutrient competition. The connection between vitamin B2 and ferroptosis in T cells represents a new understanding of how metabolic stress kills immune cells.
The study does not specify exact sample sizes for all experiments, making it difficult to assess statistical power. Most experiments were conducted in laboratory models or animal hosts rather than human patients, so results may not directly translate to human cancer treatment. The research focused on T cells and CAR-T therapy but did not extensively examine other immune cell types. Long-term safety and efficacy of vitamin B2 supplementation or SLC52A3 overexpression in human patients remain unknown. The study analyzed correlations between tumor SLC52A2 levels and patient outcomes, but correlation does not prove causation.
The Bottom Line
Based on this research, vitamin B2 supplementation may support immune function in cancer patients, though clinical trials are needed to establish optimal dosing and safety (moderate confidence). For patients receiving CAR-T cell therapy, discussing vitamin B2 status with oncologists is reasonable, as adequate intake may enhance treatment effectiveness (moderate confidence). General populations should maintain adequate dietary vitamin B2 intake as part of overall cancer risk reduction (moderate confidence based on observational data). Do not self-treat or adjust cancer therapy based on this research alone without consulting your oncology team.
Cancer patients undergoing immunotherapy, particularly CAR-T cell therapy, should be most interested in this research. People with a family history of cancer may benefit from ensuring adequate vitamin B2 intake. Researchers developing new cancer immunotherapies should consider this metabolic checkpoint. People without cancer should not assume that high-dose vitamin B2 supplementation prevents cancer, as the evidence is correlational rather than causal.
If vitamin B2 supplementation is incorporated into cancer treatment, benefits would likely emerge over weeks to months as immune cells accumulate adequate nutrient stores and function improves. The timeline for clinical trials to validate these findings is typically 3 to 5 years. Long-term effects on cancer recurrence and survival would require even longer follow-up.
Frequently Asked Questions
Does vitamin B2 supplementation help fight cancer?
Research shows that adequate vitamin B2 supports immune cell function against cancer, and higher dietary intake correlates with reduced cancer risk. However, supplementation has not yet been tested in human cancer patients, so consult your oncologist before starting supplements during cancer treatment.
How does cancer weaken the immune system through vitamin B2?
Cancer cells use a specialized transporter (SLC52A2) to grab vitamin B2 from the environment, starving immune cells of this nutrient. Without enough vitamin B2, immune cells’ power plants fail, toxic iron accumulates, and the cells die through ferroptosis, a type of cell death.
Can vitamin B2 improve CAR-T cell therapy?
Laboratory studies show that increasing vitamin B2 availability or engineering CAR-T cells to absorb more vitamin B2 significantly improved their cancer-fighting ability. Human clinical trials are needed to confirm whether this translates to better patient outcomes.
What foods are high in vitamin B2?
Excellent sources include eggs, almonds, mushrooms, salmon, chicken, and fortified cereals. Adults need 1.1 to 1.3 mg daily. Most people eating a balanced diet get enough vitamin B2 without supplementation.
Should cancer patients take vitamin B2 supplements?
This research suggests vitamin B2 may support immune function during cancer treatment, but clinical evidence in human patients is lacking. Discuss vitamin B2 status and supplementation with your oncology team before making changes, as interactions with cancer drugs are possible.
Want to Apply This Research?
- Track daily vitamin B2 intake (target 1.1 to 1.3 mg for adults) alongside immune-related symptoms such as infection frequency, energy levels, and treatment side effects. Log dietary sources of vitamin B2 including eggs, almonds, mushrooms, and fortified cereals.
- Users receiving cancer immunotherapy could use the app to set reminders for consistent vitamin B2-rich meals and track whether they’re meeting daily intake targets. For those interested in cancer prevention, the app could suggest vitamin B2 sources and monitor long-term dietary patterns.
- Establish a baseline of current vitamin B2 intake and symptoms, then monitor changes over 8 to 12 weeks if dietary adjustments are made. Track energy, infection rates, and any changes in cancer treatment response in consultation with healthcare providers. Use the app to identify dietary gaps and suggest vitamin B2-rich foods rather than relying solely on supplements.
This article summarizes research findings and is not medical advice. Vitamin B2 supplementation and cancer immunotherapy decisions should only be made in consultation with qualified oncologists and healthcare providers. Do not start, stop, or change cancer treatment based on this research alone. The findings described are from laboratory and animal studies; human clinical trials are required before these approaches become standard cancer treatment. Individual responses to vitamin B2 supplementation vary, and some people may experience side effects or drug interactions.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.